Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity-Reference-Cited by-同舟云学术

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity

Published:2023-12 Issue: Volume:78 Page:101801
ISSN:2212-8778
Container-title:Molecular Metabolism
language:en
Short-container-title:Molecular Metabolism

Author:

Friedrichsen Martin Haljeta,Endahl Lars,Kreiner Frederik Flindt,Goldwater Ronald,Kankam Martin,Toubro Søren,Nygård Sune Boris

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology

Reference59 articles.

1. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management;Neeland;Circulation,2018

2. European guidelines for obesity management in adults;Yumuk;Obes Facts,2015

3. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3·6 million adults in the UK;Bhaskaran;Lancet Diabetes Endocrinol,2018

4. Weight loss and risk reduction of obesity-related outcomes in 0.5 million people: evidence from a UK primary care database;Haase;Int J Obes (Lond),2021

5. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation;Lingvay;Lancet,2022

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incretin hormone agonists: Current and emerging pharmacotherapy for obesity management;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2024-09-03

2. Chemoreactomic study of fonturacetam effects: molecular mechanisms of influence on adipose tissue metabolism;FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology;2024-08-03

3. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis;New England Journal of Medicine;2024-07-25

4. Transforming obesity: The advancement of multi-receptor drugs;Cell;2024-07

5. Glucagon agonism in the treatment of metabolic diseases including type 2 diabetes mellitus and obesity;Diabetes, Obesity and Metabolism;2024-06-09